期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血清Cyfra21-1在卵巢癌患者中的表达及意义 被引量：1

下载PDF
导出
摘要 目的:探讨血清细胞角蛋白片段抗原21-1(Cyfra21-1)在卵巢癌患者中的表达及意义。方法:回顾性分析44例卵巢癌(A组)及54例卵巢良性病变患者(B组)术前血清Cyfra21-1及糖类抗原125(CA125)水平,并与术后病理结果等临床资料进行对比分析。结果:A组患者术前血清Cyfra21-1水平显著高于B组;Cyfra21-1诊断卵巢癌的敏感度为52.27%,特异度为94.44%,其特异性显著高于CA125(P<0.05)。卵巢癌患者分期越晚、组织分化愈差,其血清Cyfra21-1检测水平越高;早期卵巢癌患者血清Cyfra21-1的表达阳性率显著低于CA125(P<0.05)。结论:术前检测血清Cyfra21-1有助于卵巢癌的筛查而协助诊断,术前Cyfra21-1的阳性结果比CA125更能预示卵巢癌预后不良。
作者 聂妙玲 康佳丽 邓玲红 夏薇 王小霞 苏圣梅 蒋文燕
机构地区 广州市第一人民医院妇产科
出处 《实用医学杂志》 CAS 北大核心 2013年第14期2302-2304,共3页 The Journal of Practical Medicine
关键词 卵巢肿瘤 细胞角蛋白片段抗原21-1 糖类抗原125
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Bodenmuller H, Ofenloch-Hahnle B, Lane E B, et al. Lung cancer-associated keratin 19 fragments : development and biochemical characterization of the new serum assay Enzymun- Tesl CYFRA 21-1 [J]. Int J Biol Markers, 1994,9(2):75-81.
  • 2Morifuji M, Taniguchi S, Sakai H, et al. Differential expression of cytokeratin afcer orthotopic implantation of newly established human tongue cancer cell lines of defined metastatic ability [J]. Am J Pathol, 2000,156(4) : 1317-1326.
  • 3Takada M, Masuda N, Matsuura E, et al. Measurement of cytokeratin I9 fragments as a marker of lung cancer by CYFRA21-1 enzyme immunoassay [J]. Br J Cancer, 1995,71 ( 1 ) : 160-165.
  • 4Maeda Y, Segawa Y, Takigawa N, et al. CIinicaI usefuIness of serum cytokeratin 19 fragment as a tumor marker for lungcancer [Jl. Inter Med, 1996,35(10) :764-771.
  • 5Pujol J L, Grenier J, Parrat E, et al. Cytokeratins as serum markers in lung cancer: a comparisonof CYFRA21-1 and TPS[J]. Am J Reapir Crit Care Med, 1996,154(3 Pt 1):725-753.
  • 6王建英,程建新,王淑英,苏杏满.细胞角蛋白片段抗原21-1检测对卵巢癌诊断的价值[J].实用癌症杂志,2004,19(4):377-378. 被引量：4
  • 7Rustin G J, Bast RC Jr , Kelloff G J, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovariancancer [J]. Clin Cancer Res, 2004,10:3919-3926.
  • 8Moss E L, Hollingworth J, Reynolds T M. The role of CA125 in clinical practice [J]. J Clin Pathol, 2005,58:308-312.
  • 9宋晓翠,滕洪涛,张建海,殷红梅,余江,田向文.联合检测血清HE4和CA125在卵巢癌早期诊断及病情监测中的价值[J].实用医学杂志,2012,28(14):2380-2382. 被引量：71
  • 10袁莉,袁新荣,邸媛媛,李红薇,樊龙中.CA-125对上皮性卵巢癌患者预后的评估[J].广州医学院学报,2011,39(3):47-50. 被引量：7

二级参考文献24

  • 1Aletti GD,Gostout BS,Podratz KC,et al.Ovarian cancer surgical resectability:relative impact of disease,patient status,and surgeon[J].Gynecol Oncol,2006,100(26):33-37.
  • 2Bast RC,Jr.,Badgwell D,Lu Z,Marquez R,Rosen D,Liu J,et al.New tumor markers:CA125 and beyond[J].Int J Gynecol Cancer,2005,15 (Suppl 3):274-281.
  • 3Sturgeon CM,Duffy M J,Stenman UH,et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular,prostate,colorectal,breast,and ovarian cancers[J].Clin Chem,2008,54(12):e11-79.
  • 4Cooper BC,Sood AK,Davis CS,et al.Preoperative CA 125levels:an independent prognostic factor for epithelial ovarian cancer[J].Obstet Gynecol,2002,100 (12):59-64.
  • 5Boher JM,Pujol JL,Grenier J,et al.Markow model and Markers of small cell lung cancer:assessing the influence of reversible serum NSE,CYFRA 21-1 and TPS levels on prognosis[J].Br J Cancer,1999,79(9/10):1419.
  • 6Nakata B,Chung YS,Kato Y,et al.Clinical significance of serum CYFRA 21-1 in gastric cancer[J].Br J Cancer,1996,73(12):1529.
  • 7Stieber P,Schmeller N.Clinical relevance of CYFRA 21-1,TPA-IRMA and TPA-LIA-mat in urinary bladder cancer[J].Anticance Res,1996,16(6B):3793.
  • 8Nasu K,Etoh Y,Yoshimatsu J,et al.Serum levels of cytokeratin 19 fragment in cervical cancer[J].Gynecol Obstet Invest,1996,42(4):267.
  • 9Rafael M,Nagler,Mira Barak,et al.Early Diagnosis and Treatment Monitoring Roles of Tumor Markers Cyfra21-1 and TPS in Oral Squamous Cell Carcinoma[J].Cancer,1999,85(5):1018.
  • 10Riedinger J, Bonnetain F, Basuyau J, et al. Change in CA125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome [J]. Ann Oncol, 2007,18(5) :881-885.

共引文献79

同被引文献11

  • 1Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
  • 2Barry JA,Azizia MM,Hardiman PJ.Risk of endometrial,ovarian and breast cancer in w omen w ith polycystic ovary syndrome:a systematic review and meta-analysis[J].Hum Reprod Update,2014,20(5):748-758.
  • 3Da Costa Miranda V,De Souza FêdeB,Dos Anjos CH,et al.Neoadjuvant chemotherapy w ith six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery:safety and effectiveness[J].Gynecol Oncol,2014,132(2):287-291.
  • 4Rutten MJ,Van de Vrie R,Bruining A,et al.Predicting surgical outcome in patients w ith international Federation of Gynecology and Obstetrics Stage III or IV ovarian cancer using computed tomography:a systematic review of prediction models[J].Int J Gynecol Cancer,2015,25(3):407-415.
  • 5Edwards IR,Aronson JK.Adverse drug reactions:definitions,diagnosis,and management[J].The Lancet,2000,356(9237):1255-1259.
  • 6Edeline J,Boucher E,Rolland Y,et al.Comparison of tumor response by Response Evaluation Criteria in Solid Tumors(RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma[J].Cancer,2012,118(1):147-156.
  • 7Vergote I,Amant F,Kristensen G,et al.Primary surgery or neoadjuvant chemotherapy follow ed by interval debulking surgery in advanced ovarian cancer[J].Eur J Cancer,2011,47(Suppl 3):S88-S92.
  • 8Kondalsamy-Chennakesavan S,Hackethal A,Bowtell D,et al.Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4,CA125,and CEA and patient's age[J].Gynecol Oncol,2013,129(3):467-471.
  • 9Lovett KM,Liang BA,Mackey TK.Risks of online direct-toconsumer tumor markers for cancer screening[J].J Clin Oncol,2012,30(13):1411-1414.
  • 10林蓓.卵巢癌新辅助化疗相关问题[J].中国实用妇科与产科杂志,2012,28(3):177-180. 被引量：8

引证文献1

二级引证文献12

实用医学杂志
2013年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部